Therapeutic effect of renin angiotensin system inhibitors on liver fibrosis

Angiotensin-converting enzyme for noninvasive assessment of liver fibrosis in autoimmune hepatitis

(2015) Cumali Efe et al.   EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

Cirrhosis histology and Laennec staging system correlate with high portal pressure

(2013) Archana Rastogi et al.   HISTOPATHOLOGY

Angiotensin Blockade Does Not Affect Fibrosis Progression in Recurrent Hepatitis C After Liver Transplantation

(2013) O. Guillaud et al.   TRANSPLANTATION PROCEEDINGS

The Laennec staging system for histological sub-classification of cirrhosis is useful for stratification of prognosis in patients with liver cirrhosis

(2012) Seung Up Kim et al.   JOURNAL OF HEPATOLOGY

Serum angiotensin-converting enzyme level as a marker of fibrosis in patients with chronic hepatitis B

(2012) Tugrul Purnak et al.   JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM

Beneficial effects of candesartan, an angiotensin-blocking agent, on compensated alcoholic liver fibrosis - A randomized open-label controlled study

(2012) Moon Young Kim et al.   LIVER INTERNATIONAL

Effects of 1-year administration of olmesartan on portal pressure and TGF-beta1 in selected patients with cirrhosis: a randomized controlled trial

(2011) Hisashi Hidaka et al.   JOURNAL OF GASTROENTEROLOGY

873 PROGRESSION OF NAFLD IN HUMANS IS ASSOCIATED WITH THE ACTIVATION OF THE RENIN-ANGIOTENSIN SYSTEM

(2011) J. Vergniol et al.   JOURNAL OF HEPATOLOGY

Histological subclassification of cirrhosis using the Laennec fibrosis scoring system correlates with clinical stage and grade of portal hypertension

(2011) Moon Young Kim et al.   JOURNAL OF HEPATOLOGY

Obesity, inflammation, and liver cancer

(2011) Beicheng Sun et al.   JOURNAL OF HEPATOLOGY

Valsartan decreases TGF-β1 production and protects against chlorhexidine digluconate-induced liver peritoneal fibrosis in rats

(2010) Yi-Maun Subeq et al.   CYTOKINE

The Effects of Angiotensin Blocking Agents on the Progression of Liver Fibrosis in the HALT-C Trial Cohort

(2010) Barham K. Abu Dayyeh et al.   DIGESTIVE DISEASES AND SCIENCES

Effects of losartan on hepatic expression of nonphagocytic NADPH oxidase and fibrogenic genes in patients with chronic hepatitis C

(2009) Jordi Colmenero et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

Inflammation and Liver Cancer

(2009) C. Berasain et al.   Annals of the New York Academy of Sciences

Angiotensin-converting-enzyme 2 inhibits liver fibrosis in mice

(2009) Christoph H. Österreicher et al.   HEPATOLOGY

Deletion of angiotensin II type I receptor reduces hepatic steatosis

(2009) Yoshitaka Nabeshima et al.   JOURNAL OF HEPATOLOGY

The effect of angiotensin-blocking agents on liver fibrosis in patients with hepatitis C

(2009) Kathleen E. Corey et al.   LIVER INTERNATIONAL

Angiotensin II antagonists in patients with recurrent hepatitis C virus infection after liver transplantation

(2009) Evangelos Cholongitas et al.   LIVER INTERNATIONAL

Relationship between angiotensin-(1-7) and angiotensin II correlates with hemodynamic changes in human liver cirrhosis

(2009) Walkíria Wingester Vilas-Boas et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Diagnostic Accuracy of Serum Hyaluronic Acid, FIBROSpect II, and YKL-40 for Discriminating Fibrosis Stages in Chronic Hepatitis C

(2008) Preeti Mehta et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Serum hyaluronic acid with serum ferritin accurately predicts cirrhosis and reduces the need for liver biopsy in C282Y hemochromatosis

(2008) Darrell H. G. Crawford et al.   HEPATOLOGY

Angiotensin receptor blockers are superior to angiotensin-converting enzyme inhibitors in the suppression of hepatic fibrosis in a bile duct-ligated rat model

(2008) Moon Young Kim et al.   JOURNAL OF GASTROENTEROLOGY